Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Administration (FDA) as 3 separate brand name medications—Ozempic®, Wegovy®, and Rybelsus®. Each brand name comes with its own associated indications, preparations, and dosages to consider. The Rybelsus® tablet brand demonstrates efficacy in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). Ozempic® injectable brand provides an additional indication of reducing the risk of major adverse cardiovascular events in patients with and without T2DM. In a recent development, semaglutide received FDA approval under the brand name Wegovy®, which is an injection used for promoting weight loss in individuals dealing with obesity and overweight. Due to the increased complexity involved, special attention is necessary for every FDA-approved indication and current off-label use.
Copyright © 2025, StatPearls Publishing LLC.